Praxis Precision Medicines, Inc. (PRAX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRAX Revenue Growth
Revenue Breakdown (FY 2024)
PRAX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PRAX Revenue Analysis (2018–2025)
As of May 8, 2026, Praxis Precision Medicines, Inc. (PRAX) generated trailing twelve-month (TTM) revenue of $-92,000. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, PRAX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $8.6 million in 2024.
Revenue diversification analysis shows PRAX's business is primarily driven by License (77%), and Upfront Payment (23%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), NRIX (+54.0% YoY), and ARVN (-0.3% YoY). Compare PRAX vs ACAD →
PRAX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRAXCurrent | $-92,000 | - | - | - | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 NRIX | $84M | +54.0% | +36.3% | -340.2% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 OVID | $7M | +1181.3% | -10.5% | -585.2% |
PRAX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-140,000 | - | $-326,198,000 | - |
| 2024 | $8.6M | +249.5% | $-143,860,000 | -1682.0% | $-200,165,000 | -2340.3% |
| 2023 | $2.4M | - | $-84,319,000 | -3445.8% | $-126,373,000 | -5164.4% |
| 2022 | $0 | - | $-154,440,000 | - | $-214,986,000 | - |
| 2021 | $0 | - | $0 | - | $-167,332,000 | - |
| 2020 | $0 | - | $0 | - | $-61,968,000 | - |
| 2019 | $0 | - | $-679,000 | - | $-35,789,000 | - |
| 2018 | $0 | - | $-1,000 | - | $-22,719,000 | - |
Full PRAX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PRAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRAX — Frequently Asked Questions
Quick answers to the most common questions about buying PRAX stock.
Is PRAX's revenue growth accelerating or slowing?
PRAX TTM revenue: $-92000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PRAX's long-term revenue growth rate?
Praxis Precision Medicines, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is PRAX's revenue distributed by segment?
PRAX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.